$75.1 M

BLPH Mkt cap, 22-Jan-2021
Bellerophon Therapeutics Net income (Q3, 2020)-7.9 M
Bellerophon Therapeutics EBIT (Q3, 2020)-8.3 M
Bellerophon Therapeutics Cash, 30-Sept-202054 M
Bellerophon Therapeutics EV23 M

Bellerophon Therapeutics Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

6.3m14.5m28.8m16.6m9.9m

Prepaid Expenses

5.4m3.4m650.0k405.0k

Current Assets

29.5m26.5m35.6m17.4m10.4m

PP&E

1.8m1.4m1.0m664.0k316.0k

Total Assets

38.4m29.7m36.8m18.4m13.1m

Accounts Payable

1.6m2.8m3.9m2.8m3.1m

Short-term debt

658.0k

Current Liabilities

8.1m6.5m7.1m7.5m7.6m

Long-term debt

1.7m

Total Debt

2.3m

Total Liabilities

8.1m11.7m39.4m14.5m9.5m

Common Stock

131.0k569.0k587.0k46.0k

Preferred Stock

Additional Paid-in Capital

130.9m142.2m176.2m179.8m193.3m

Retained Earnings

(100.7m)(124.5m)(179.3m)(176.5m)(189.8m)

Total Equity

30.3m18.0m(2.6m)3.9m3.6m

Financial Leverage

1.3 x1.7 x-14.2 x4.8 x3.7 x

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

62.9m48.5m23.9m1.3m1.3m3.9m13.5m11.0m32.3m28.4m23.4m19.6m20.7m16.8m12.8m8.6m59.3m54.0m

Prepaid Expenses

2.0m1.8m1.4m5.7m5.4m6.4m6.4m5.4m3.9m3.0m2.5m1.7m948.0k825.0k712.0k349.0k903.0k633.0k

Current Assets

73.6m60.9m46.9m23.1m18.6m17.5m23.2m20.4m39.4m34.8m28.8m22.5m21.7m17.7m13.7m9.0m60.3m54.7m

PP&E

1.6m1.5m1.8m1.7m1.6m1.5m1.3m1.2m1.1m935.0k845.0k755.0k576.0k488.0k401.0k270.0k228.0k198.0k

Total Assets

75.2m62.4m49.2m31.2m26.3m22.8m25.8m22.4m40.9m35.9m29.8m23.6m24.8m20.6m16.6m11.6m62.7m57.0m

Accounts Payable

659.0k966.0k934.0k641.0k2.0m2.2m3.9m2.8m2.8m4.6m4.1m4.4m2.6m2.8m2.3m2.2m2.8m3.8m

Short-term debt

669.0k680.0k692.0k

Current Liabilities

12.8m11.2m8.6m7.3m6.2m4.8m6.1m5.5m6.4m8.4m9.0m9.1m7.3m6.7m7.0m6.8m6.6m9.0m

Long-term debt

1.9m1.7m1.8m1.5m1.3m1.1m

Total Debt

1.9m1.7m1.8m2.2m2.0m1.8m

Total Liabilities

12.8m11.2m8.6m7.3m6.2m4.8m25.0m23.1m25.2m33.7m37.6m19.7m14.5m9.1m9.3m9.4m9.3m11.2m

Common Stock

129.0k129.0k130.0k135.0k139.0k145.0k330.0k352.0k550.0k574.0k578.0k587.0k689.0k689.0k689.0k49.0k95.0k95.0k

Preferred Stock

Additional Paid-in Capital

129.4m129.8m130.2m131.5m132.8m134.9m144.1m146.4m170.3m176.9m178.3m178.9m186.9m192.2m192.3m196.8m251.9m252.3m

Retained Earnings

(67.1m)(78.7m)(89.9m)(107.7m)(112.9m)(117.1m)(143.6m)(147.6m)(155.2m)(175.2m)(186.7m)(175.6m)(177.3m)(181.4m)(185.7m)(194.7m)(198.6m)(206.5m)

Total Equity

62.4m51.2m40.5m23.9m20.1m18.0m800.0k(787.0k)15.7m2.2m(7.8m)3.9m10.3m11.5m7.3m2.1m53.4m45.9m

Financial Leverage

1.2 x1.2 x1.2 x1.3 x1.3 x1.3 x32.2 x-28.4 x2.6 x16.2 x-3.8 x6 x2.4 x1.8 x2.3 x5.4 x1.2 x1.2 x

Bellerophon Therapeutics Cash Flow

Bellerophon Therapeutics Ratios

USDQ1, 2015

Financial Leverage

1.2 x